Skip to main content
PCSA
NASDAQ Life Sciences

Processa Pharmaceuticals' PCS12852 Licensing Agreement with Intact Therapeutics Terminates

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.28
Mkt Cap
$5.166M
52W Low
$2.05
52W High
$19.635
52W Position info
11% above low
Off High info
88% below high
Rel. Volume
Market data snapshot near publication time

PCSA is trading near its 52-week low of $2.05 (11% above the low).

Summary

Processa Pharmaceuticals' binding term sheet with Intact Therapeutics for PCS12852 expired without a definitive license agreement, ending the potential partnership.


Key Events · M&A and Partnerships · PCSA

  • Material Agreement Termination

    The binding term sheet dated June 17, 2025, with Intact Therapeutics regarding PCS12852 expired on February 12, 2026.

  • No Definitive License Agreement

    A definitive license agreement for PCS12852 was not executed, nor was the related proposed amendment to the License Agreement with Yuhan Corporation.

  • No Further Obligations

    Following the expiration, neither Processa Pharmaceuticals nor Intact Therapeutics has any additional obligations under the term sheet.


Analysis · PCSA · Life Sciences

Processa Pharmaceuticals announced the expiration of its binding term sheet with Intact Therapeutics for the drug candidate PCS12852. This means a definitive license agreement was not executed, effectively ending the potential partnership and development path for PCS12852 with Intact Therapeutics. For a micro-cap biotechnology company, the termination of a material agreement related to a drug candidate represents a significant setback, potentially impacting future development, funding, and revenue prospects for that asset.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCSA was trading at $2.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $2.05 to $19.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCSA - Latest Insights

PCSA
Nov 05, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.85
Real-time Price: $1.86 info
Change: +$0.010 (+0.54%) info
Market Cap: $5.205M info
PCSA
Oct 29, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.86 info
Change: -$0.090 (-5%) info
Market Cap: $5.205M info
PCSA
Oct 29, 2026, 8:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.89
Real-time Price: $1.86 info
Change: -$0.030 (-2%) info
Market Cap: $5.205M info
PCSA
Oct 09, 2026, 4:03 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.86 info
Change: +$0.390 (+27%) info
Market Cap: $5.205M info
PCSA
Oct 09, 2026, 4:02 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.86 info
Change: +$0.390 (+27%) info
Market Cap: $5.205M info